These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 1992569)

  • 1. Advanced prostatic carcinoma. Early versus late endocrine therapy.
    Kozlowski JM; Ellis WJ; Grayhack JT
    Urol Clin North Am; 1991 Feb; 18(1):15-24. PubMed ID: 1992569
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endocrine treatment of prostate cancer.
    Tammela T
    J Steroid Biochem Mol Biol; 2004 Nov; 92(4):287-95. PubMed ID: 15663992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
    Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
    Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Androgen deprivation therapy for advanced prostate cancer: why does it fail and can its effects be prolonged?
    Singer EA; Golijanin DJ; Messing EM
    Can J Urol; 2008 Dec; 15(6):4381-7. PubMed ID: 19046491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [First line therapy in the treatment of metastatic prostate cancer].
    Sakai H; Kanetake H
    Gan To Kagaku Ryoho; 2003 Jan; 30(1):43-9. PubMed ID: 12557704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Androgen deprivation therapy for prostate cancer: current status and future prospects.
    Miyamoto H; Messing EM; Chang C
    Prostate; 2004 Dec; 61(4):332-53. PubMed ID: 15389811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hormonal therapy for locally advanced prostate cancer.
    Einstein AB
    NCI Monogr; 1988; (7):171-4. PubMed ID: 3050536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of endocrine therapy in the management of local and distant recurrence of prostate cancer following radical prostatectomy or radiation therapy.
    Mayer FJ; Crawford ED
    Urol Clin North Am; 1994 Nov; 21(4):707-15. PubMed ID: 7974899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer.
    Pummer K; Lehnert M; Stettner H; Hubmer G
    Eur Urol; 1997; 32 Suppl 3():81-5. PubMed ID: 9267791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hormonal ablation therapy for metastatic prostatic carcinoma: a review.
    Leewansangtong S; Soontrapa S
    J Med Assoc Thai; 1999 Feb; 82(2):192-205. PubMed ID: 10087729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.
    Martinez AA; Demanes DJ; Galalae R; Vargas C; Bertermann H; Rodriguez R; Gustafson G; Altieri G; Gonzalez J
    Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1322-31. PubMed ID: 16029788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early versus delayed androgen deprivation for prostate cancer: new fuel for an old debate.
    Ryan CJ; Small EJ
    J Clin Oncol; 2005 Nov; 23(32):8225-31. PubMed ID: 16278477
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Androgen receptor gene amplification at primary progression predicts response to combined androgen blockade as second line therapy for advanced prostate cancer.
    Palmberg C; Koivisto P; Kakkola L; Tammela TL; Kallioniemi OP; Visakorpi T
    J Urol; 2000 Dec; 164(6):1992-5. PubMed ID: 11061898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Unresolved questions in hormonal therapy for prostate cancer].
    Oishi K
    Gan To Kagaku Ryoho; 1994 Sep; 21(12):1928-33. PubMed ID: 8085843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent progress in hormonal therapy for advanced prostate cancer.
    Daskivich TJ; Oh WK
    Curr Opin Urol; 2006 May; 16(3):173-8. PubMed ID: 16679855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hormonal therapy in prostatic carcinoma.
    Resnick MI
    Urology; 1984 Nov; 24(5 Suppl):18-23. PubMed ID: 6388092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The nonsteroidal effects of diethylstilbestrol: the rationale for androgen deprivation therapy without estrogen deprivation in the treatment of prostate cancer.
    Scherr DS; Pitts WR
    J Urol; 2003 Nov; 170(5):1703-8. PubMed ID: 14532759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined androgen blockade: the gold standard for metastatic prostate cancer.
    McLeod DG; Crawford ED; DeAntoni EP
    Eur Urol; 1997; 32 Suppl 3():70-7. PubMed ID: 9267789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.
    Okegawa T; Nutahara K; Higashihara E
    J Urol; 2008 Oct; 180(4):1342-7. PubMed ID: 18707699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment of advanced prostatic cancer].
    Hedlund PO
    Lakartidningen; 2000 Aug; 97(32-33):3466-9. PubMed ID: 11037588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.